On April 28 2010 Vitro Diagnostics Inc signed a contract to jointly manufacture and distribute stem cell analysis tools with HemoGenix Inc.
HemoGenix owns patented and patent-pending technology for analysis of stem cells known as the HALO(R) assay platform which is based on advanced measurement of ATP cellular content. HALO(R) assays are now industry standard methods for quality and potency determination of hematopoietic stem cells and also allow sophisticated analysis of toxic effects of drugs and new drug candidates including cancer chemotherapeutic agents.
The agreement with Vitro will allow expansion of assay platforms from HemoGenix, in particular, LUMENESC for mesenchymal stem cells (MSC) and LumiSTEM for induced pluripotent stem cells (iPS). IPS technology allows the use of reprogrammed adult cells to achieve properties of embryonic stem cells including the ability to differentiate into any type of cell in the body without use or sacrifice of embryos and as a consequence, any of the ethical or religious issues involved with the use of embryonic stem cells.